ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancers
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Head and Neck Squamous-Cell Carcinoma
Platinum Resistant High Grade Epithelial Ovarian Cancer

Interventions: Drug: ABBV-400

First Posted Date: 2023-10-16

Last Posted Date: 2024-11-25

Lead Sponsor: AbbVie

Target Recruit Count: 260

Registration Number: NCT06084481

Locations: 🇦🇺
Chris O'Brien Lifehouse /ID# 262765, Camperdown, New South Wales, Australia
🇮🇱
Rambam Health Care Campus /ID# 256649, Haifa, H_efa, Israel
🇵🇷
Pan American Center for Oncology Trials /ID# 262903, Rio Piedras, Puerto Rico

and more 50 locations

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

Phase 1

Not yet recruiting

Conditions: Healthy Volunteers

Interventions: Drug: ABBV-903

First Posted Date: 2023-10-11

Last Posted Date: 2023-10-11

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT06078202

Locations: 🇺🇸
Acpru /Id# 259438, Grayslake, Illinois, United States

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Venetoclax

First Posted Date: 2023-10-06

Last Posted Date: 2024-06-21

Lead Sponsor: AbbVie

Registration Number: NCT06070948

Locations: 🇺🇸
Acpru /Id# 259897, Grayslake, Illinois, United States

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

Recruiting

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2023-10-05

Last Posted Date: 2024-11-25

Lead Sponsor: AbbVie

Target Recruit Count: 500

Registration Number: NCT06068842

Locations: 🇯🇵
Kindai University Hospital /ID# 257890, Osakasayama-shi, Osaka, Japan
🇨🇭
University Hospital Zurich /ID# 256678, Zurich, Zuerich, Switzerland
🇨🇳
National Taiwan University Hospital /ID# 261542, Taipei City, Taipei, Taiwan

and more 16 locations

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ABBV-787

First Posted Date: 2023-10-05

Last Posted Date: 2024-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT06068868

Locations: 🇺🇸
University of Chicago Medical /ID# 252764, Chicago, Illinois, United States
🇺🇸
City of Hope /ID# 253727, Duarte, California, United States
🇺🇸
University of California Davis Health /ID# 252723, Sacramento, California, United States

and more 21 locations

A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants

Phase 3

Active, not recruiting

Conditions: Masseter Muscle Prominence

Interventions: Drug: Placebo
Drug: BOTOX

First Posted Date: 2023-10-05

Last Posted Date: 2024-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 249

Registration Number: NCT06068855

Locations: 🇧🇪
Da Vinci Clinic /ID# 246731, Beerse, Antwerpen, Belgium
🇧🇪
Evolve Clinic /ID# 246729, Schilde, Antwerpen, Belgium
🇧🇪
Universitair Ziekenhuis Brussel /ID# 246311, Jette, Bruxelles-Capitale, Belgium

and more 24 locations

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lutikizumab Dose B
Drug: Lutikizumab Dose A

First Posted Date: 2023-10-05

Last Posted Date: 2024-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT06067568

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc /ID# 260986, Cypress, California, United States
🇺🇸
Acpru /Id# 259029, Grayslake, Illinois, United States
🇺🇸
PPD Clinical Research Unit - Austin /ID# 260141, Austin, Texas, United States

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Risankizumab SC
Drug: Placebo for risankizumab

First Posted Date: 2023-10-03

Last Posted Date: 2025-01-10

Lead Sponsor: AbbVie

Target Recruit Count: 276

Registration Number: NCT06063967

Locations: 🇺🇸
Southwest Gastroenterology /ID# 256619, Oak Lawn, Illinois, United States
🇺🇸
Gi Alliance - Arizona Digestive Health - Sun City /ID# 268178, Sun City, Arizona, United States
🇺🇸
Southern California Res. Ctr. /ID# 256612, Coronado, California, United States

and more 138 locations

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Conditions: Uterine Fibroids (UF)

First Posted Date: 2023-09-28

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 1600

Registration Number: NCT06058728

Locations: 🇺🇸
Dorsata /ID# 252675, Arlington, Virginia, United States

A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

Recruiting

Conditions: Acute Myeloid Leukemia

First Posted Date: 2023-09-28

Last Posted Date: 2024-12-24

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT06058741

Locations: 🇮🇹
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 259535, Bologna, Emilia-Romagna, Italy
🇮🇹
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 260963, Meldola, Reggio Emilia, Italy
🇮🇹
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 260683, Rome, Roma, Italy

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy